17.06.2012 - The Danish world market leader in enzyme technology, Novozymes A/S, will supply a large scale bioethanol production plant in China.
Baegsvaard – The deal was agreed during a visit from Hu Jintao, President of the People's Republic of China, in Copenhagen. Novozymes and its partner Shenqquan first announced the deal last month. China's Shengquan Group will start producing cellulosic ethanol in July, the company said. According to Shenqquan, it will be the first in the world to do so on a commercial scale. The production will also be cost-competitive given that the feedstock, conventional ethanol, is a waste product from Shengquan's current production. The Chinese company is investing US $100m in the new groundbreaking facility. Novozymes will supply the enabling enzyme technology.
"When Shengquan opens its facility next month, it will be the first in the world," explains Steen Riisgaard, President and CEO of Novozymes. "It's fantastic to finally see this industry go commercial; for more than 10 years our researchers have worked to bring down the cost of producing ethanol from agricultural residues and household and industrial waste." Shengquan is a producer of furfural for resin production in the foundry industry. Furfural is produced from corncob xylose, with the cellulose from the corncob left behind as a waste product. Using Novozymes' enzymes, Shengquan will now be able to convert the cellulose into higher-value sugars that can be fermented to ethanol. Shengquan will market the ethanol as an industrial solvent. "In order to continue to grow our country's economy at the same time as reducing our dependency on natural resources and minimizing the environmental impact, we need to start thinking of waste as an extremely valuable resource," comments Yi Lin Tang, President and Chairman of Shengquan Group. "Basically, we want and need to nurture a green and circular bioeconomy which is less dependent on fossil resources."
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.
27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).
21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.
21.04.2016 For up to US$685m (€606m), Dutch ArgenX has outlicensed its human antibody programme ARGX-115 to AbbVie. The pre-clinical immuno-oncology candidate targets a protein believed to contribute to immunosuppressive effects of T-cells.
19.04.2016 British drug developer Heptares Therapeutics and mAb maker Kymab Ltd have partnered up in yet another immuno-oncology collaboration. The companies plan to discover antibody meds targeting a superfamily of receptors.
15.04.2016 Not every company is put off by the current stock market climate. Swiss biopharma company GeNeuro has gone public at Euronext Paris, raising €33m in the process. Others, meanwhile, have to find different ways to raise money.
13.04.2016 Despite political disturbances, 2015 was a good year for the biotech scene in Switzerland. Net sales increased by 5.1% to CHF5,133m and 400 additional people found jobs in the sector. As usual, the new numbers were presented at the annual Swiss Biotech Day – which set new records as well.